Last reviewed · How we verify

Selinexor, dexamethasone, ixazomib, pomalidomide

Multiple Myeloma Research Consortium · Phase 1 active Small molecule

Selinexor, dexamethasone, ixazomib, pomalidomide is a Small molecule drug developed by Multiple Myeloma Research Consortium. It is currently in Phase 1 development. Also known as: Selinexor: XPOVIO.

At a glance

Generic nameSelinexor, dexamethasone, ixazomib, pomalidomide
Also known asSelinexor: XPOVIO
SponsorMultiple Myeloma Research Consortium
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Selinexor, dexamethasone, ixazomib, pomalidomide

What is Selinexor, dexamethasone, ixazomib, pomalidomide?

Selinexor, dexamethasone, ixazomib, pomalidomide is a Small molecule drug developed by Multiple Myeloma Research Consortium.

Who makes Selinexor, dexamethasone, ixazomib, pomalidomide?

Selinexor, dexamethasone, ixazomib, pomalidomide is developed by Multiple Myeloma Research Consortium (see full Multiple Myeloma Research Consortium pipeline at /company/multiple-myeloma-research-consortium).

Is Selinexor, dexamethasone, ixazomib, pomalidomide also known as anything else?

Selinexor, dexamethasone, ixazomib, pomalidomide is also known as Selinexor: XPOVIO.

What development phase is Selinexor, dexamethasone, ixazomib, pomalidomide in?

Selinexor, dexamethasone, ixazomib, pomalidomide is in Phase 1.

Related